Jerome Bourgault
Overview
Explore the profile of Jerome Bourgault including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maltais-Payette I, Bourgault J, Gauthier M, Biertho L, Marceau S, Julien F, et al.
Physiol Rep
. 2025 Jan;
13(3):e70171.
PMID: 39868884
Metabolic dysfunction-associated steatotic liver disease (MASLD) describes liver diseases caused by the accumulation of triglycerides in hepatocytes (steatosis) as well as the resulting inflammation and fibrosis. Previous studies have demonstrated...
2.
Manikpurage H, Ricard J, Houessou U, Bourgault J, Gagnon E, Gobeil E, et al.
Atherosclerosis
. 2024 Dec;
401:119083.
PMID: 39674127
Background And Aims: Estimating the genetic risk of coronary artery disease (CAD) is now possible by aggregating data from genome-wide association studies (GWAS) into polygenic risk scores (PRS). Combining multiple...
3.
Gagnon E, Girard A, Bourgault J, Abner E, Gill D, Theriault S, et al.
Eur Heart J Open
. 2024 Jun;
4(3):oeae043.
PMID: 38933427
Aims: Anticoagulants are routinely used by millions of patients worldwide to prevent blood clots. Yet, problems with anticoagulant therapy remain, including a persistent and cumulative bleeding risk in patients undergoing...
4.
Gagnon E, Bourgault J, Gobeil E, Theriault S, Arsenault B
Atherosclerosis
. 2024 May;
393:117558.
PMID: 38703417
Background: Carriers of the E40K loss-of-function variant in Angiopoietin-like 4 (ANGPTL4), have lower plasma triglyceride levels as well as lower rates of coronary artery disease (CAD) and type 2 diabetes...
5.
Gobeil E, Bourgault J, Mitchell P, Houessou U, Gagnon E, Girard A, et al.
Eur Heart J
. 2024 Jan;
45(9):707-721.
PMID: 38243829
Background And Aims: RNA-based, antibody-based, and genome editing-based therapies are currently under investigation to determine if the inhibition of angiopoietin-like protein-3 (ANGPTL3) could reduce lipoprotein-lipid levels and atherosclerotic cardiovascular disease...
6.
Gagnon E, Manikpurage H, Mitchell P, Girard A, Gobeil E, Bourgault J, et al.
iScience
. 2023 Jul;
26(7):107127.
PMID: 37456853
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent disease with no specific drug therapy. High-throughput metabolomics present an unprecedented opportunity to identify biomarkers and potentially causal risk factors for...
7.
Gagnon E, Girard A, Gobeil E, Bourgault J, Couture C, Mitchell P, et al.
iScience
. 2023 Apr;
26(4):106376.
PMID: 37013190
Genome-wide association studies (GWAS) have identified hundreds of genetic variants associated with body weight but the biological relevance of most remains unexplored. Given the critical role of the brain in...
8.
Bourgault J, Abner E, Manikpurage H, Pujol-Gualdo N, Laisk T, Gobeil E, et al.
Gastroenterology
. 2023 Feb;
164(6):953-965.e3.
PMID: 36736436
Background & Aims: Acute pancreatitis (AP) is a complex disease and the leading cause of gastrointestinal disease-related hospital admissions. Few therapeutic options exist for AP prevention. Blood proteins with causal...
9.
Gagnon E, Pelletier W, Gobeil E, Bourgault J, Manikpurage H, Maltais-Payette I, et al.
Commun Med (Lond)
. 2022 Oct;
2:130.
PMID: 36249462
Background: Observational studies have linked adiposity and especially abdominal adiposity to liver fat accumulation and non-alcoholic fatty liver disease. These traits are also associated with type 2 diabetes and coronary...
10.
Gobeil E, Maltais-Payette I, Taba N, Briere F, Ghodsian N, Abner E, et al.
Metabolites
. 2022 May;
12(5).
PMID: 35629944
Non-alcoholic fatty liver disease (NAFLD) is a complex disease associated with premature mortality. Its diagnosis is challenging, and the identification of biomarkers causally influenced by NAFLD may be clinically useful....